Lyell Wealth Management LP Reduces Position in Zoetis Inc. $ZTS

Key Points

• Lyell Wealth Management LP has reduced its stake in Zoetis Inc. by 3.4%, selling 2,294 shares, bringing its total holdings to 65,082 shares valued at approximately $10.15 million.
• Zoetis recently reported better-than-expected earnings with an EPS of $1.76 for the last quarter, exceeding analysts' estimates of $1.62, alongside revenue of $2.46 billion.
• The company has declared a $0.50 quarterly dividend, with the ex-dividend date set for October 31st, offering a yield of 1.4% based on its current payout ratio of 34.42%.

Lyell Wealth Management LP lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 3.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 65,082 shares of the company's stock after selling 2,294 shares during the quarter. Lyell Wealth Management LP's holdings in Zoetis were worth $10,150,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also modified their holdings of the company. Nova Wealth Management Inc. purchased a new position in shares of Zoetis during the 1st quarter worth $25,000. 1248 Management LLC purchased a new position in shares of Zoetis during the 1st quarter worth $27,000. Saudi Central Bank purchased a new position in shares of Zoetis during the 1st quarter worth $29,000. REAP Financial Group LLC boosted its stake in shares of Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company's stock worth $31,000 after acquiring an additional 131 shares during the last quarter. Finally, Cornerstone Planning Group LLC boosted its stake in shares of Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after acquiring an additional 88 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Stock Up 0.6%

Shares of ZTS stock opened at $144.15 on Monday. The stock has a market cap of $63.88 billion, a P/E ratio of 24.81, a PEG ratio of 2.31 and a beta of 0.90. Zoetis Inc. has a 52 week low of $139.34 and a 52 week high of $193.49. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The company's fifty day simple moving average is $148.73 and its two-hundred day simple moving average is $153.65.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping the consensus estimate of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business's quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be paid a $0.50 dividend. The ex-dividend date is Friday, October 31st. This represents a $2.00 annualized dividend and a yield of 1.4%. Zoetis's payout ratio is presently 34.42%.

Analysts Set New Price Targets

ZTS has been the topic of a number of analyst reports. Piper Sandler lifted their target price on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Argus restated a "buy" rating and set a $190.00 target price on shares of Zoetis in a research note on Tuesday, September 9th. Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Weiss Ratings restated a "hold (c-)" rating on shares of Zoetis in a research note on Wednesday, October 8th. Finally, Leerink Partnrs cut shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Four equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $196.71.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.